Class Action Suit Filed Against ARS Pharmaceuticals Over Stock Drop
News related to:ARS Pharmaceuticals Inc · 2 min read
Kaplan Fox & Kilsheimer LLP has announced that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) on behalf of investors who purchased or otherwise acquired ARS securities between March 9, 2026, and June 24, 2026 (the "Class Period").
The lawsuit alleges that on June 24, 2026, after the market closed, ARS published a press release providing an update on payer access for neffy. Following this news, the price of ARS stock fell $2.52 per share, or 23.9%, to close at $8.02 per share on June 25, 2026.
Kaplan Fox & Kilsheimer LLP is urging investors who believe they may have suffered losses to contact the firm. Investors can reach out by emailing [email protected] or by calling (646) 315-9003. The firm notes that if you are a member of the proposed class, you may move the court no later than October 5, 2026, to serve as a lead plaintiff for the purported class. However, the firm emphasizes that you do not need to seek to become a lead plaintiff to share in any possible recovery.
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented. The firm is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America, the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act, $800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.